South Korea · Delayed Price · Currency is KRW KBIO COMPANY Statistics
Total Valuation
KBIO COMPANY has a market cap or net worth of KRW 31.07 billion. The enterprise value is 27.75 billion.
| Market Cap | 31.07B |
| Enterprise Value | 27.75B |
Important Dates
The next estimated earnings date is Wednesday, March 18, 2026.
| Earnings Date | Mar 18, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
KBIO COMPANY has 115.50 million shares outstanding. The number of shares has increased by 1.36% in one year.
| Current Share Class | 115.50M |
| Shares Outstanding | 115.50M |
| Shares Change (YoY) | +1.36% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 77.21M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.37 |
| PB Ratio | 0.30 |
| P/TBV Ratio | 0.59 |
| P/FCF Ratio | 5.30 |
| P/OCF Ratio | 5.27 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 57.15, with an EV/FCF ratio of 4.73.
| EV / Earnings | -2.22 |
| EV / Sales | 0.33 |
| EV / EBITDA | 57.15 |
| EV / EBIT | n/a |
| EV / FCF | 4.73 |
Financial Position
The company has a current ratio of 9.17, with a Debt / Equity ratio of 0.01.
| Current Ratio | 9.17 |
| Quick Ratio | 7.78 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | 1.60 |
| Debt / FCF | 0.13 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -16.53% and return on invested capital (ROIC) is -0.95%.
| Return on Equity (ROE) | -16.53% |
| Return on Assets (ROA) | -0.25% |
| Return on Invested Capital (ROIC) | -0.95% |
| Return on Capital Employed (ROCE) | -0.47% |
| Weighted Average Cost of Capital (WACC) | 9.61% |
| Revenue Per Employee | 2.15B |
| Profits Per Employee | -319.86M |
| Employee Count | 36 |
| Asset Turnover | 0.69 |
| Inventory Turnover | 13.80 |
Taxes
In the past 12 months, KBIO COMPANY has paid 320.22 million in taxes.
| Income Tax | 320.22M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -1.10% in the last 52 weeks. The beta is 1.02, so KBIO COMPANY's price volatility has been similar to the market average.
| Beta (5Y) | 1.02 |
| 52-Week Price Change | -1.10% |
| 50-Day Moving Average | 244.90 |
| 200-Day Moving Average | 261.36 |
| Relative Strength Index (RSI) | 63.69 |
| Average Volume (20 Days) | 2,156,526 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, KBIO COMPANY had revenue of KRW 83.85 billion and -12.47 billion in losses. Loss per share was -107.46.
| Revenue | 83.85B |
| Gross Profit | 12.81B |
| Operating Income | -494.22M |
| Pretax Income | -18.40B |
| Net Income | -12.47B |
| EBITDA | 485.51M |
| EBIT | -494.22M |
| Loss Per Share | -107.46 |
Balance Sheet
The company has 53.88 billion in cash and 775.19 million in debt, with a net cash position of 53.11 billion or 459.80 per share.
| Cash & Cash Equivalents | 53.88B |
| Total Debt | 775.19M |
| Net Cash | 53.11B |
| Net Cash Per Share | 459.80 |
| Equity (Book Value) | 103.82B |
| Book Value Per Share | 467.81 |
| Working Capital | 61.87B |
Cash Flow
In the last 12 months, operating cash flow was 5.90 billion and capital expenditures -39.88 million, giving a free cash flow of 5.86 billion.
| Operating Cash Flow | 5.90B |
| Capital Expenditures | -39.88M |
| Free Cash Flow | 5.86B |
| FCF Per Share | 50.74 |
Margins
Gross margin is 15.28%, with operating and profit margins of -0.59% and -14.88%.
| Gross Margin | 15.28% |
| Operating Margin | -0.59% |
| Pretax Margin | -21.95% |
| Profit Margin | -14.88% |
| EBITDA Margin | 0.58% |
| EBIT Margin | -0.59% |
| FCF Margin | 6.99% |
Dividends & Yields
KBIO COMPANY does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.36% |
| Shareholder Yield | -1.36% |
| Earnings Yield | -40.15% |
| FCF Yield | 18.86% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on April 27, 2017. It was a reverse split with a ratio of 0.1.
| Last Split Date | Apr 27, 2017 |
| Split Type | Reverse |
| Split Ratio | 0.1 |
Scores
KBIO COMPANY has an Altman Z-Score of 2.96 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.96 |
| Piotroski F-Score | 4 |